Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;12(12):7571-7590.
doi: 10.21037/jtd-2019-thym-10.

Autoimmune disorders and paraneoplastic syndromes in thymoma

Affiliations
Review

Autoimmune disorders and paraneoplastic syndromes in thymoma

Torsten Gerriet Blum et al. J Thorac Dis. 2020 Dec.

Abstract

Thymomas are counted among the rare tumour entities which are associated with autoimmune disorders (AIDs) and paraneoplastic syndromes (PNS) far more often than other malignancies. Through its complex immunological function in the context of the selection and maturation of T cells, the thymus is at the same time highly susceptible to disruptive factors caused by the development and growth of thymic tumours. These T cells, which are thought to develop to competent immune cells in the thymus, can instead adopt autoreactive behaviour due to the uncontrolled interplay of thymomas and become the trigger for AID or PNS affecting numerous organs and tissues within the human body. While myasthenia gravis is the most prevalent PNS in thymoma, numerous others have been described, be they related to neurological, cardiovascular, gastrointestinal, haematological, dermatological, endocrine or systemic disorders. This review article sheds light on the pathophysiology, epidemiology, specific clinical features and therapeutic options of the various forms as well as courses and outcomes of AID/PNS in association with thymomas. Whenever suitable and backed by the limited available evidence, the perspectives from both the thymoma and the affected organ/tissue will be highlighted. Specific issues addressed are the prognostic significance of thymectomy on myasthenia gravis and other thymoma-associated AID/PND and further the impact and safety of immunotherapies on AID and PND relating to thymomas.

Keywords: Thymoma; autoimmune disease; paraneoplastic syndrome (PNS); thymic tumour.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at: http://dx.doi.org/10.21037/jtd-2019-thym-10). The series “Thymoma” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Similar articles

Cited by

References

    1. Marx A, Chan JK, Coindre JM, et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol 2015;10:1383-95. 10.1097/JTO.0000000000000654 - DOI - PMC - PubMed
    1. Auche M. Des nevrites peripheriques chez les cancereux. Rev Med 1890;10:785-807.
    1. Weigert C. Pathologisch-anatomischer Beitrag zur Erb’schen Krankheit (Myasthenia gravis). Neurol Zentralbl 1901;20:597-601.
    1. Padda SK, Yao X, Antonicelli A, et al. Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. J Thorac Oncol 2018;13:436-46. 10.1016/j.jtho.2017.11.118 - DOI - PMC - PubMed
    1. Rajan A, Zhao C. Deciphering the biology of thymic epithelial tumors. Mediastinum 2019;3:36. 10.21037/med.2019.08.03 - DOI - PMC - PubMed